Diagnostic and Treatment Center

Summary

Diagnostic and Treatment Center is a medical facility located in Schofield, Wisconsin. This center is recognized for care of Lung Cancer, Breast Cancer, Prostate Cancer, Lymphoma, Breast cancer and other specialties. Diagnostic and Treatment Center is involved with conducting 101 clinical trials across 195 conditions. There are 10 research doctors associated with this hospital, such as Seth O. Fagbemi, Adedayo A. Onitilo, Chady A. Leon, MD, and Michael Husak.

Top PIs

Clinical Trials running at Diagnostic and Treatment Center

Prostate Cancer

Laryngeal Cancer

Oropharyngeal Carcinoma

Bladder Cancer

Breast Cancer

Brain Tumor

Throat Cancer

Lip and Oral Cavity Cancer

Oral Cancers

Prostate Adenocarcinoma

Apalutamide + Hormone and Radiation Therapies

for Prostate Cancer

This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading and extend time without disease spreading compared to the usual approach.

Recruiting

2 awards

Phase 3

Standard Therapy + Surgery/Radiation

for Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.

Recruiting

2 awards

Phase 3

30 criteria